A prevascularized subcutaneous device-less site for islet and cellular transplantation

Nature Biotechnology

Volumn 33, Issue 5, 2015, Pages 518-523

  Pepper, Andrew R ^a   Gala Lopez, Boris ^a   Pawlick, Rena ^a   Merani, Shaheed ^a   Kin, Tatsuya ^a,b   Shapiro, A M James ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALS; MOBILE SECURITY;

CELL ENCAPSULATIONS; INFLAMMATORY RESPONSE; ISLET TRANSPLANTATION; MOUSE STRAIN; NORMOGLYCEMIA; STREPTOZOTOCIN; SUBCUTANEOUS DEVICES; VASCULAR ACCESS;

GRAFTS;

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; KERATINOCYTE GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; GLUCOSE BLOOD LEVEL;

ALLOGENEIC RESTRICTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ENCAPSULATION; CELL TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE RELEASE; EXTRACELLULAR MATRIX; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MESENCHYMAL STEM CELL; MICROENVIRONMENT; MOUSE; MOUSE STRAIN; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SUBCUTANEOUS FAT; SUBSTITUTION THERAPY; VASCULAR ACCESS; VASCULARIZATION; ANIMAL; BIOLOGICAL THERAPY; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; GRAFT SURVIVAL; HUMAN; LIVER; NEOVASCULARIZATION, PATHOLOGIC; PANCREAS ISLET TRANSPLANTATION; PATHOLOGY; TRANSLATIONAL RESEARCH;

MUS;

ANIMALS; BLOOD GLUCOSE; CELL- AND TISSUE-BASED THERAPY; DIABETES MELLITUS, EXPERIMENTAL; GRAFT SURVIVAL; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; LIVER; MICE; NEOVASCULARIZATION, PATHOLOGIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84929148312     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3211     Document Type: Article

References (38)

1. Shapiro, A.M. et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343, 230-238 (2000).
2. Ryan, E.A. et al. Five-year follow-up after clinical islet transplantation. Diabetes 54, 2060-2069 (2005).
3. Shapiro, A.M. & Ricordi, C. in Textbook of Organ Transplantation, vol. 1. (eds. Kirk, A.D. et al.) 1-1,904 (Wiley-Blackwell, 2014).
4. Harlan, D.M., Kenyon, N.S., Korsgren, O. & Roep, B.O. Current advances and travails in islet transplantation. Diabetes 58, 2175-2184 (2009).
5. Plesner, A. & Verchere, C.B. Advances and challenges in islet transplantation: islet procurement rates and lessons learned from suboptimal islet transplantation. J. Transplant. 2011, 979527 (2011).
6. Ricordi, C. & Strom, T.B. Clinical islet transplantation: advances and immunological challenges. Nat. Rev. Immunol. 4, 259-268 (2004).
7. Shapiro, A.M. in Islet transplantation and beta cell replacement therapy. (eds. Shapiro, A.M. & Shaw, J.A.) (Informa Healthcare, New York, London, 2007).
8. Brissova, M. & Powers, A.C. Revascularization of transplanted islets: can it be improved? Diabetes 57, 2269-2271 (2008).
9. Pepper, A.R., Gala-Lopez, B., Ziff, O. & Shapiro, A.M. Revascularization of transplanted pancreatic islets and role of the transplantation site. Clin. Dev. Immunol. 2013, 352315 (2013).
10. Merani, S., Toso, C., Emamaullee, J. & Shapiro, A.M. Optimal implantation site for pancreatic islet transplantation. Br. J. Surg. 95, 1449-1461 (2008).
11. Vériter, S., Gianello, P. & Dufrane, D. Bioengineered sites for islet cell transplantation. Curr. Diab. Rep. 13, 745-755 (2013).
12. Nishimura, R. et al. Assessment for revascularization of transplanted pancreatic islets at subcutaneous site in mice with a highly sensitive imaging system. Transplant. Proc. 43, 3239-3240 (2011).
13. Saito, T. et al. Reversal of diabetes by the creation of neo-islet tissues into a subcutaneous site using islet cell sheets. Transplantation 92, 1231-1236 (2011).
14. Sakata, N. et al. Strategy for clinical setting in intramuscular and subcutaneous islet transplantation. Diabetes Metab. Res. Rev. 30, 1-10 (2014).
15. Simeonovic, C.J., Dhall, D.P., Wilson, J.D. & Lafferty, K.J. A comparative study of transplant sites for endocrine tissue transplantation in the pig. Aust. J. Exp. Biol. Med. Sci. 64, 37-41 (1986).
16. Rajab, A. Islet transplantation: alternative sites. Curr. Diab. Rep. 10, 332-337 (2010).
17. Anderson, J.M., Rodriguez, A. & Chang, D.T. Foreign body reaction to biomaterials. Semin. Immunol. 20, 86-100 (2008).
18. Anderson, J.M. Biological response to materials. Annu. Rev. Mater. Res. 31, 81-110 (2001).
19. Ward, W.K. A review of the foreign-body response to subcutaneously-implanted devices: the role of macrophages and cytokines in biofouling and fibrosis. J. Diabetes Sci. Technol. 2, 768-777 (2008).
20. Fujiwara, N. & Kobayashi, K. Macrophages in inflammation. Curr. Drug Targets Inflamm. Allergy 4, 281-286 (2005).
21. van Amerongen, M.J., Molema, G., Plantinga, J., Moorlag, H. & van Luyn, M.J. Neovascularization and vascular markers in a foreign body reaction to subcutaneously implanted degradable biomaterial in mice. Angiogenesis 5, 173-180 (2002).
22. Grainger, D.W. All charged up about implanted biomaterials. Nat. Biotechnol. 31, 507-509 (2013).
23. Sharkawy, A.A., Klitzman, B., Truskey, G.A. & Reichert, W.M. Engineering the tissue which encapsulates subcutaneous implants. I. Diffusion properties. J. Biomed. Mater. Res. 37, 401-412 (1997).
24. Sharkawy, A.A., Klitzman, B., Truskey, G.A. & Reichert, W.M. Engineering the tissue which encapsulates subcutaneous implants. III. Effective tissue response times. J. Biomed. Mater. Res. 40, 598-605 (1998).
25. Sharkawy, A.A., Klitzman, B., Truskey, G.A. & Reichert, W.M. Engineering the tissue which encapsulates subcutaneous implants. II. Plasma-tissue exchange properties. J. Biomed. Mater. Res. 40, 586-597 (1998).
26. Pileggi, A. et al. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation 81, 1318-1324 (2006).
27. Zhang, L. et al. Zwitterionic hydrogels implanted in mice resist the foreign-body reaction. Nat. Biotechnol. 31, 553-556 (2013).
28. Olsson, R., Olerud, J., Pettersson, U. & Carlsson, P.O. Increased numbers of low-oxygenated pancreatic islets after intraportal islet transplantation. Diabetes 60, 2350-2353 (2011).
29. Hellerström, C., Andersson, A., Korsgren, O., Jansson, L. & Sandler, S. Aspects of pancreatic islet transplantation in diabetes mellitus. Baillieres Clin. Gastroenterol. 3, 851-863 (1989).
30. Korsgren, O. et al. Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia 51, 227-232 (2008).
31. Pileggi, A., Ricordi, C., Alessiani, M. & Inverardi, L. Factors influencing Islet of Langerhans graft function and monitoring. Clin. Chim. Acta 310, 3-16 (2001).
32. Nyqvist, D., Kohler, M., Wahlstedt, H. & Berggren, P.O. Donor islet endothelial cells participate in formation of functional vessels within pancreatic islet grafts. Diabetes 54, 2287-2293 (2005).
33. Zhang, H.F., Maslov, K., Stoica, G. & Wang, L.V. Functional photoacoustic microscopy for high-resolution and noninvasive in vivo imaging. Nat. Biotechnol. 24, 848-851 (2006).
34. Costa, P.Z. & Soares, R. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci. 92, 1037-1045 (2013).
35. Tamarat, R. et al. Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am. J. Pathol. 164, 457-466 (2004).
36. Brekken, R.A. et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 60, 5117-5124 (2000).
37. Kin, T. et al. Risk factors for islet loss during culture prior to transplantation. Transpl. Int. 21, 1029-1035 (2008).
38. Ricordi, C., Lacy, P.E. & Scharp, D.W. Automated islet isolation from human pancreas. Diabetes 38 (suppl. 1), 140-142 (1989).